What are peptides for weight loss?
Peptides for weight loss, also searched as weight loss peptides and fat loss peptides, can mean two different things. In the medical literature it usually means GLP-1 receptor agonists such as semaglutide and tirzepatide, which are licensed prescription medicines. Separately, some research peptides and related compounds are grouped under the same heading in the marketplace. This page covers both, keeps them apart, and states what each body of evidence shows. Stackpure sells research materials only, not the licensed medicines.
What the trials of licensed GLP-1 medicines show
These are large randomized trials of prescription medicines used with lifestyle intervention. They are the evidence most people mean when they ask about peptides for weight loss, and they do not apply to research peptides.
| Medicine | Trial result | Source |
|---|---|---|
| Semaglutide 2.4 mg weekly | Body weight -14.9% vs -2.4% with placebo at 68 weeks in 1,961 adults with obesity, plus lifestyle intervention; 86.4% vs 31.5% lost 5% or more | Wilding 2021 |
| Tirzepatide weekly | -15.0% (5 mg), -19.5% (10 mg) and -20.9% (15 mg) vs -3.1% with placebo at 72 weeks | Jastreboff 2022 |
| GLP-1 receptor agonists, 55 trials | Higher risk of cholelithiasis (RR 1.46) and GERD (RR 2.19) vs placebo; little or no effect on other GI or biliary events | Chiang 2025 |
The most common adverse events in both trials were gastrointestinal and mostly mild to moderate. In the semaglutide trial, 4.5% stopped treatment for gastrointestinal events versus 0.8% with placebo (Wilding 2021).
Which research peptides are discussed for weight loss?
The compounds below are research materials. The evidence is smaller and mostly from animals, and none of it matches the licensed-medicine trials above.
| Compound | What the sources show | Overview |
|---|---|---|
| AOD-9604 | Raised fat oxidation without hyperglycaemia and did not compete for the growth hormone receptor in obese mice (Heffernan 2001) | What Is AOD-9604? |
| Tesofensine | Small-molecule triple reuptake inhibitor, not a peptide; 14-week weight change +0.5% placebo vs -2.8% at 1.0 mg, with a dose-related heart rate rise (Astrup 2008) | What Is Tesofensine? |
| 5-Amino-1MQ | NNMT inhibitor; limited weight and fat gain and improved glucose tolerance in diet-induced obese mice, no human data (Babula 2024) | What Is 5-Amino-1MQ? |
| HGH fragment 176-191 | No data for the fragment itself in the sources checked; findings are for the related fragment AOD9604 | AOD-9604 vs HGH Fragment 176-191 |
| Tesamorelin | Visceral fat fell versus placebo in HIV lipodystrophy trials (Falutz 2010) | What Is Tesamorelin? |
Are peptides safe for weight loss?
For licensed GLP-1 medicines, the trials report mostly mild to moderate gastrointestinal events, and a 55-trial meta-analysis found increased risks of cholelithiasis and GERD (Chiang 2025). For research compounds, the sources checked report no human safety data for AOD-9604 or 5-Amino-1MQ, and tesofensine raised heart rate in a dose-related way (Astrup 2008). Product identity is also a safety issue: a published case found a black-market vial contained a different protein from the one expected (Kohler 2010).
Where can I buy peptides for weight loss?
Licensed GLP-1 medicines are prescription products. Research peptides are sold for laboratory use only. If you source research materials, use the supplier checklist and compare certificates of analysis. Stackpure lists weight loss peptides for research, each with a COA for the batch.
What the sources do not show
- Most findings on research compounds are from mice, and the one weight trial cited for tesofensine is in people with Parkinson or Alzheimer disease.
- No source checked compares the research compounds with each other or with the licensed medicines.
- Stackpure makes no weight loss claims and does not give dosing guidance.
Related research products and tools
- Weight loss peptides
- AOD-9604 peptide vial
- Tesofensine capsules
- 5-Amino-1MQ capsules
- Peptide calculator
See also peptide side effects.
Frequently Asked Questions
What are the best peptides for weight loss?
The checked sources do not support ranking research compounds. The largest trial evidence is for the licensed medicines semaglutide and tirzepatide (Wilding 2021, Jastreboff 2022). For research compounds the evidence is mouse data and one small trial dataset.
What are fat loss peptides?
Fat loss peptides is a search term for the same category. See the tables above for what each compound has been studied for.
Do peptides work for weight loss?
Licensed GLP-1 medicines lowered body weight by 14.9% to 20.9% in trials with lifestyle intervention, versus 2.4% to 3.1% with placebo (Wilding 2021, Jastreboff 2022). The sources checked do not show that research peptides do the same in people.
Key References
- Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021. PubMed 33567185
- Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022. PubMed 35658024
- Chiang CH, et al. Glucagon-like peptide-1 receptor agonists and gastrointestinal adverse events: a systematic review and meta-analysis. Gastroenterology. 2025. PubMed 40499738
- Heffernan M, et al. Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Int J Obes Relat Metab Disord. 2001. PubMed 11673763
- Astrup A, et al. Weight loss produced by tesofensine in patients with Parkinson or Alzheimer disease. Obesity. 2008. PubMed 18356831
- Babula JJ, et al. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes Obes Metab. 2024. PubMed 39161060
- Falutz J, et al. Effects of tesamorelin in HIV-infected patients with excess abdominal fat: a pooled analysis of two phase 3 trials. J Clin Endocrinol Metab. 2010. PubMed 20554713
- Kohler M, et al. Detection of His-tagged Long-R3-IGF-I in a black market product. Growth Horm IGF Res. 2010. PubMed 20675162
For research use only. Not for human consumption.